<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">akusherstvo</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics, Gynecology and Reproduction</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство, Гинекология и Репродукция</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7347</issn><issn pub-type="epub">2500-3194</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2313-7347/ob.gyn.rep.2026.688</article-id><article-id custom-type="elpub" pub-id-type="custom">akusherstvo-2706</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ОRIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group></article-categories><title-group><article-title>Treatment selection and anovulation predictors in patients with obesity and oligo-/amenorrhea assisted by neural network technology</article-title><trans-title-group xml:lang="ru"><trans-title>Выбор лечения для восстановления овуляции у пациенток с ожирением и олиго-/аменореей с помощью нейросетевой технологии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9524-8962</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дикке</surname><given-names>Г. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Dikke</surname><given-names>G. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дикке Галина Борисовна - д.м.н., проф.</p><p>190013 Санкт-Петербург, Московский проспект, д. 22, литера М</p></bio><bio xml:lang="en"><p>Galina B. Dikke, MD, Dr Sci Med, Prof.</p><p>22 Litera M, Moskovskiy Prospekt, Saint Petersburg 190013</p></bio><email xlink:type="simple">galadikke@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5961-5400</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мудров</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Mudrov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мудров Виктор Андреевич - д.м.н., проф.</p><p>Scopus Author ID: 57204736023</p><p>eLibrary SPIN-code: 5821-3203</p><p>672000 Чита, ул. Горького, д. 39а</p></bio><bio xml:lang="en"><p>Viktor A. Mudrov - MD, Dr Sci Med, Prof.</p><p>Scopus Author ID: 57204736023</p><p>eLibrary SPIN-code: 5821-3203</p><p>39a Gorky Street, Chita 672000</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Эфендиева</surname><given-names>Р. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Efendieva</surname><given-names>R. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Эфендиева Рамина Мавлюдиновна</p><p>367000 Махачкала, площадь Ленина, д. 1</p></bio><bio xml:lang="en"><p>Ramina M. Efendieva - MD.</p><p>1 Lenin Square, Makhachkala 367000</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7729-1606</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абусуева</surname><given-names>З. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Abusueva</surname><given-names>Z. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Абусуева Зухра Абусуевна - д.м.н., проф.</p><p>367000 Махачкала, площадь Ленина, д. 1</p></bio><bio xml:lang="en"><p>Zukhra A. Abusueva - MD, Dr Sci Med, Prof.</p><p>1 Lenin Square, Makhachkala 367000</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ЧОУ ДПО «Академия медицинского образования имени Ф.И. Иноземцева»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Inozemtsev Academy of Medical Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Читинская государственная медицинская академия» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Chita State Medical Academy, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Дагестанский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Dagestan State Medical University, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>12</day><month>03</month><year>2026</year></pub-date><volume>20</volume><issue>1</issue><fpage>34</fpage><lpage>50</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Dikke G.B., Mudrov V.A., Efendieva R.M., Abusueva Z.A., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Дикке Г.Б., Мудров В.А., Эфендиева Р.М., Абусуева З.А.</copyright-holder><copyright-holder xml:lang="en">Dikke G.B., Mudrov V.A., Efendieva R.M., Abusueva Z.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gynecology.su/jour/article/view/2706">https://www.gynecology.su/jour/article/view/2706</self-uri><abstract><sec><title>Introduction</title><p>Introduction. Approximately 20 % of reproductive age women are obese, and more than half of them experience menstrual irregularities, anovulation, and infertility.</p></sec><sec><title>Aim</title><p>Aim: to determine predictors of ovulation restoration and to develop a model for individual treatment selection in patients with obesity and oligo-/amenorrhea based on neural network technology.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. The prospective randomized controlled study included 80 women – patients with obesity and oligo-/amenorrhea, divided into 2 groups, who received the following therapy for 6 months: 40 patients (group I) – a combination of myoinositol, D-chiroinositol, folic acid and manganese, the other 40 patients (group II) – metformin. After treatment, patients from both groups were divided into two clusters based on the "anovulation/ovulation" criterion. Anthropometric parameters were determined, pelvic organs ultrasound was performed, laboratory tests (indicators of carbohydrate and fat metabolism, amino acids and peptides, hormonal status, blood cytokine levels, inflammation markers, and blood micronutrient composition) were performed. To create a model for predicting ovulation restoration, a multilayer perceptron procedure was used. The diagnostic value of the prognostic model was determined using ROC analysis.</p></sec><sec><title>Results</title><p>Results. The average age of the patients was 27.9 ± 3.8 years, with the average body mass index (BMI) 33,4 [31.2; 34.0] kg/m2. The following parameters were identified as significant anovulation predictors using neural network analysis: waist-to-hip ratio (WHR), menstrual cycle duration, Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), C-reactive protein, leptin, follicle-stimulating hormone, 25-hydroxycalciferol (vitamin D), and tumour necrosis factor alpha. Because these parameters reflect the metabolic profile in patients, interventions to restore ovulation should primarily be aimed at correcting it. The developed model for predicting the onset of ovulation has a sensitivity of 100 %, specificity of 80 %, accuracy of 93.8 %; the area under the ROC curve is 0.985 (p &lt; 0.001), which allows to consider it sufficiently informative for specific drug selection. For practical purposes, an online calculator for individual drug selection has been developed (accuracy – 91.7 %).</p></sec><sec><title>Conclusion</title><p>Conclusion. An integrated approach based on neural network analysis of study parameters available for wide clinical practice is promising for predicting the onset of ovulation while using a specific drug due to its high information content.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Введение</title><p>Введение. Около 20 % женщин репродуктивного возраста страдают ожирением, и у более половины из них наблюдаются нарушения менструального цикла, ановуляция и бесплодие.</p></sec><sec><title>Цель</title><p>Цель: определить предикторы восстановления овуляции и разработать модель индивидуального выбора лечения у пациенток с ожирением и олиго-/аменореей на основе нейросетевой технологии.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В проспективное рандомизированное контролируемое исследование были включены 80 пациенток с ожирением и олиго-/аменореей, которые были распределены на 2 группы, в течение 6 месяцев получавших следующую терапию: 40 пациенток (группа I) – комбинацию миоинозитола, D-хироинозитола, фолиевой кислоты и марганца, другие 40 пациенток (группа II) – метформин. После лечения пациентки обеих групп были распределены на 2 кластера по признаку «ановуляция/овуляция». Определяли антропометрические показатели, выполняли ультразвуковое исследование (УЗИ) органов малого таза, измеряли параметры углеводного и жирового обмена, гормонального статуса, содержание в крови аминокислот, пептидов, цитокинов, маркеров воспаления, изучали микронутриентный состав крови. Для создания модели прогноза восстановления овуляции использовали процедуру многослойного перцептрона. Прогностическую ценность модели определяли с помощью ROC-анализа.</p></sec><sec><title>Результаты</title><p>Результаты. Возраст пациенток в среднем составил 27,9 ± 3,8 лет, индекс массы тела (ИМТ) – 33,4 [31,2; 34,0] кг/м2. В качестве значимых предикторов восстановления овуляции с помощью нейросетевого анализа были определены: отношение объема талии к объему бедер (ОТ/ОБ), продолжительность менструального цикла, индекс инсулинорезистентности (англ. Homeostasis Model Assessment of Insulin Resistance, HOMA-IR), С-реактивный белок, лептин, фолликулостимулирующий гормон, 25-гидроксикальциферол (витамин D), фактор некроза опухоли альфа. Поскольку большинство показателей отражают метаболический профиль пациенток, то вмешательства для восстановления овуляции необходимо в первую очередь направить на его коррекцию. Разработанная модель для прогнозирования наступления овуляции обладает чувствительностью 100 %, специфичностью 80 %, точностью 93,8 %, площадь под ROC-кривой составляет 0,985 (p &lt; 0,001), что позволяет считать модель достаточно информативной для выбора конкретного лекарственного средства. Для практических целей разработан онлайн калькулятор индивидуального выбора препарата (точность – 91,7 %).</p></sec><sec><title>Заключение</title><p>Заключение. Комплексный подход, основанный на нейросетевом анализе параметров исследования, доступных для широкой клинической практики, является перспективным для прогнозирования наступления овуляции при применении конкретного препарата ввиду его высокой информативности.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>олигоменорея</kwd><kwd>аменорея</kwd><kwd>овуляция</kwd><kwd>ановуляция</kwd><kwd>нейросетевой анализ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>oligomenorrhea</kwd><kwd>amenorrhea</kwd><kwd>ovulation</kwd><kwd>anovulation</kwd><kwd>neural network analysis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Авторы заявляют об отсутствии финансовой поддержки</funding-statement><funding-statement xml:lang="en">The authors declare no funding</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–50. https://doi.org/10.1016/S0140-6736(23)02750-2.</mixed-citation><mixed-citation xml:lang="en">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–50. https://doi.org/10.1016/S0140-6736(23)02750-2.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Алфёрова В.И., Мустафина С.В. Распространенность ожирения во взрослой популяции Российской Федерации (обзор литературы). Ожирение и метаболизм. 2022;19(1):96–105. https://doi.org/10.14341/omet12809.</mixed-citation><mixed-citation xml:lang="en">Alferova V.I., Mustafina S.V. Prevalence of obesity in the adult population of the Russian Federation (literature review). [Rasprostranennost' ozhireniya vo vzrosloj populyacii Rossijskoj Federacii (obzor literatury)]. Ozhirenie i metabolizm. 2022;19(1):96–105. (In Russ.). https://doi.org/10.14341/omet12809.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Annarahayu L., Dewi Y.L.R., Adriyani R.B. Meta-analysis the effect of obesity and stress on menstrual cycle disorder. J Matern Child Health. 2021;6(4):423–35. https://doi.org/10.26911/thejmch.2021.06.04.0.</mixed-citation><mixed-citation xml:lang="en">Annarahayu L., Dewi Y.L.R., Adriyani R.B. Meta-analysis the effect of obesity and stress on menstrual cycle disorder. J Matern Child Health. 2021;6(4):423–35. https://doi.org/10.26911/thejmch.2021.06.04.0</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sermondade N., Huberlant S., Bourhis-Lefebvre V. et al. Female obesity is negatively associated with live birth rate following IVF: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(4):439–51. https://doi.org/10.1093/humupd/dmz011.</mixed-citation><mixed-citation xml:lang="en">Sermondade N., Huberlant S., Bourhis-Lefebvre V. et al. Female obesity is negatively associated with live birth rate following IVF: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(4):439–51. https://doi.org/10.1093/humupd/dmz011.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Westerman R., Kuhnt A.K. Metabolic risk factors and fertility disorders: A narrative review of the female perspective. Reprod Biomed Soc Online. 2021;14:66–74. https://doi.org/10.1016/j.rbms.2021.09.002.</mixed-citation><mixed-citation xml:lang="en">Westerman R., Kuhnt A.K. Metabolic risk factors and fertility disorders: A narrative review of the female perspective. Reprod Biomed Soc Online. 2021;14:66–74. https://doi.org/10.1016/j.rbms.2021.09.002.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng L., Yang L., Guo Z. et al. Obesity and its impact on female reproductive health: unraveling the connections. Front Endocrinol (Lausanne). 2024;14:1326546. https://doi.org/10.3389/fendo.2023.1326546.</mixed-citation><mixed-citation xml:lang="en">Zheng L., Yang L., Guo Z. et al. Obesity and its impact on female reproductive health: unraveling the connections. Front Endocrinol (Lausanne). 2024;14:1326546. https://doi.org/10.3389/fendo.2023.1326546.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Giviziez C.R., Sanchez E.G.M., Lima Y.A.R., Approbato M.S. Association of overweight and consistent anovulation among infertile women with regular menstrual cycle: a case-control study. Rev Bras Ginecol Obstet. 2021;43(11):834–9. https://doi.org/10.1055/s-0041-1739464.</mixed-citation><mixed-citation xml:lang="en">Giviziez C.R., Sanchez E.G.M., Lima Y.A.R., Approbato M.S. Association of overweight and consistent anovulation among infertile women with regular menstrual cycle: a case-control study. Rev Bras Ginecol Obstet. 2021;43(11):834–9. https://doi.org/10.1055/s-0041-1739464.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bloom M.S., Perkins N.J., Sjaarda L.A. et al. Adiposity is associated with anovulation independent of serum free testosterone: a prospective cohort study. Paediatr Perinat Epidemiol. 2021;35(2):174–83. https://doi.org/10.1111/ppe.12726.</mixed-citation><mixed-citation xml:lang="en">Bloom M.S., Perkins N.J., Sjaarda L.A. et al. Adiposity is associated with anovulation independent of serum free testosterone: a prospective cohort study. Paediatr Perinat Epidemiol. 2021;35(2):174–83. https://doi.org/10.1111/ppe.12726.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Herman R., Kravos N.A., Jensterle M. et al. Metformin and insulin resistance: a review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport. Int J Mol Sci. 2022;23(3):1264. https://doi.org/10.3390/ijms23031264.</mixed-citation><mixed-citation xml:lang="en">Herman R., Kravos N.A., Jensterle M. et al. Metformin and insulin resistance: a review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport. Int J Mol Sci. 2022;23(3):1264. https://doi.org/10.3390/ijms23031264.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Pu R., Shi D., Gan T. et al. Effects of metformin in obesity treatment in different populations: a meta-analysis. Ther Adv Endocrinol Metab. 2020;11:2042018820926000. https://doi.org/10.1177/2042018820926000.</mixed-citation><mixed-citation xml:lang="en">Pu R., Shi D., Gan T. et al. Effects of metformin in obesity treatment in different populations: a meta-analysis. Ther Adv Endocrinol Metab. 2020;11:2042018820926000. https://doi.org/10.1177/2042018820926000.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Ruthia Y.S., Al-Mandeel H., AlSanawi H. et al. Ovulation induction by metformin among obese versus non-obese women with polycystic ovary syndrome. Saudi Pharm J. 2017;25(5):795–800. https://doi.org/10.1016/j.jsps.2016.12.001.</mixed-citation><mixed-citation xml:lang="en">Al-Ruthia Y.S., Al-Mandeel H., AlSanawi H. et al. Ovulation induction by metformin among obese versus non-obese women with polycystic ovary syndrome. Saudi Pharm J. 2017;25(5):795–800. https://doi.org/10.1016/j.jsps.2016.12.001.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Guan Y., Wang D., Bu H. et al. The effect of metformin on polycystic ovary syndrome in Overweight women: a systematic review and metaanalysis of randomized controlled trials. Int J Endocrinol. 2020;2020:5150684. https://doi.org/10.1155/2020/5150684.</mixed-citation><mixed-citation xml:lang="en">Guan Y., Wang D., Bu H. et al. The effect of metformin on polycystic ovary syndrome in Overweight women: a systematic review and metaanalysis of randomized controlled trials. Int J Endocrinol. 2020;2020:5150684. https://doi.org/10.1155/2020/5150684.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">DiNicolantonio J.J., O'Keefe J.Н. Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart. 2022;9(1):e001989. https://doi.org/10.1136/openhrt-2022-001989.</mixed-citation><mixed-citation xml:lang="en">DiNicolantonio J.J., O'Keefe J.Ню Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart. 2022;9(1):e001989. https://doi.org/10.1136/openhrt-2022-001989.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Доброхотова Ю.Э., Лапина И.А., Чирвон Т.Г., Таранов В.В. Новые возможности интегративной терапии пациенток с СПКЯ и нарушениями углеводного и липидного обмена. Результаты сравнительного исследования. РМЖ. Мать и дитя. 2020;3(3):1–6. https://doi.org/10.32364/2618-8430-2020-3-3-169-173.</mixed-citation><mixed-citation xml:lang="en">Dobrokhotova Yu.E., Lapina I.A., Chirvon T.G., Taranov V.V. New prospects of the integrative therapy for polycystic ovary syndrome in women with the disorders of carbohydrate and lipid metabolism: a comparative study. [Novye vozmozhnosti integrativnoj terapii pacientok s SPKYa i narusheniyami uglevodnogo i lipidnogo obmena. Rezul'taty sravnitel'nogo issledovaniya]. RMZh. Mat' i ditya. 2020;3(3):1–6. (In Russ.). https://doi.org/10.32364/2618-8430-2020-3-3-169-173.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Дикке Г.Б., Новичков Д.А., Зулкарнеева Э.М. и др. Опыт лечения больных с аномальными маточными кровотечениями на фоне овуляторной дисфункции. Акушерство и гинекология. 2024;(3):142–52. https://doi.org/10.18565/aig.2024.28.</mixed-citation><mixed-citation xml:lang="en">Dikke G.B., Novichkov D.A., Zulkarneeva E.M. et al. Experience of treating patients with abnormal uterine bleeding associated with ovulatory dysfunction. [Opyt lecheniya bol'nyh s anomal'nymi matochnymi krovotecheniyami na fone ovulyatornoj disfunkcii]. Akusherstvo i ginekologiya. 2024;(3):142–52. (In Russ.). https://doi.org/10.18565/aig.2024.28.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Greff D., Juhász A.E., Váncsa S. et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023;21(1):10. https://doi.org/10.1186/s12958-023-01055-z.</mixed-citation><mixed-citation xml:lang="en">Greff D., Juhász A.E., Váncsa S. et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and metaanalysis of randomized controlled trials. Reprod Biol Endocrinol. 2023;21(1):10. https://doi.org/10.1186/s12958-023-01055-z.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sharpe A., Morley L.C., Tang T. et al. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;12(12):CD013505. https://doi.org/10.1002/14651858.CD013505.</mixed-citation><mixed-citation xml:lang="en">Sharpe A., Morley L.C., Tang T. et al. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;12(12):CD013505. https://doi.org/10.1002/14651858.CD013505.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao H., Xing C., Zhang J., He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021;18(1):171. https://doi.org/10.1186/s12978-021-01207-7.</mixed-citation><mixed-citation xml:lang="en">Zhao H., Xing C., Zhang J., He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 202118(1):171. https://doi.org/10.1186/s12978-021-01207-7.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chait A., den Hartigh L.J. Adipose tissue distribution, Inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 2020;7:22. https://doi.org/10.3389/fcvm.2020.00022.</mixed-citation><mixed-citation xml:lang="en">Chait A., den Hartigh L.J. Adipose tissue distribution, Inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 2020;7:22. https://doi.org/10.3389/fcvm.2020.00022.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ke J., Feng Y., Chen Z. Association between waist circumference and female infertility in the United States. PLoS One. 2023;18(12):e0295360. https://doi.org/10.1371/journal.pone.0295360.</mixed-citation><mixed-citation xml:lang="en">Ke J., Feng Y., Chen Z. Association between waist circumference and female infertility in the United States. PLoS One. 2023;18(12):e0295360. https://doi.org/10.1371/journal.pone.0295360.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao X., Luo M., Tian Q. Therapeutic selection for abnormal uterine bleeding with ovulatory dysfunction: a cross-sectional study in Chinese women. Future Sci OA. 2025;11(1):2459001. https://doi.org/10.1080/20565623.2025.2459001.</mixed-citation><mixed-citation xml:lang="en">Zhao X., Luo M., Tian Q. Therapeutic selection for abnormal uterine bleeding with ovulatory dysfunction: a cross-sectional study in Chinese women. Future Sci OA. 2025;11(1):2459001. https://doi.org/10.1080/20565623.2025.2459001.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Niu J., Lu M., Liu B. Association between insulin resistance and abnormal menstrual cycle in Chinese patients with polycystic ovary syndrome. J Ovarian Res. 2023;16(1):45. https://doi.org/10.1186/s13048-02301122-4.</mixed-citation><mixed-citation xml:lang="en">Niu J., Lu M., Liu B. Association between insulin resistance and abnormal menstrual cycle in Chinese patients with polycystic ovary syndrome. J Ovarian Res. 2023;16(1):45. https://doi.org/10.1186/s13048-02301122-4.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Karnatak R., Agarwal A., Asnani M., Singh R. The effect of insulin resistance on ovulation induction with clomiphene citrate in non-polycystic ovary syndrome (PCOS) women. Cureus. 2022;14(7):e27433. https://doi.org/10.7759/cureus.27433.</mixed-citation><mixed-citation xml:lang="en">Karnatak R., Agarwal A., Asnani M., Singh R. The effect of insulin resistance on ovulation induction with clomiphene citrate in non-polycystic ovary syndrome (PCOS) women. Cureus. 2022;14(7):e27433. https://doi.org/10.7759/cureus.27433.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Armanini D., Boscaro M., Bordin L., Sabbadin C. Controversies in the pathogenesis, diagnosis and treatment of PCOS: focus on insulin resistance, inflammation, and hyperandrogenism. Int J Mol Sci. 2022;23(8):4110. https://doi.org/10.3390/ijms23084110.</mixed-citation><mixed-citation xml:lang="en">Armanini D., Boscaro M., Bordin L., Sabbadin C. Controversies in the pathogenesis, diagnosis and treatment of PCOS: focus on insulin resistance, inflammation, and hyperandrogenism. Int J Mol Sci. 2022;23(8):4110. https://doi.org/10.3390/ijms23084110.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Baraskar K., Thakur P., Shrivastava R., Shrivastava V. Female obesity: association with endocrine disruption and reproductive dysfunction. Obesity Medicine. 2021;28:100375. https://doi.org/10.1016/j.obmed.2021.100375.</mixed-citation><mixed-citation xml:lang="en">Baraskar K., Thakur P., Shrivastava R., Shrivastava V. Female obesity: association with endocrine disruption and reproductive dysfunction. Obesity Medicine. 2021;28:100375. https://doi.org/10.1016/j.obmed.2021.100375.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Rudnicka E., Suchta K., Grymowicz M. et al. Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci. 2021;22(7):3789. https://doi.org/10.3390/ijms22073789.</mixed-citation><mixed-citation xml:lang="en">Rudnicka E., Suchta K., Grymowicz M. et al. Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci. 2021;22(7):3789. https://doi.org/10.3390/ijms22073789.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Aboeldalyl S., James C., Seyam E. et al. The role of chronic inflammation in polycystic ovarian syndrome – a systematic review and meta-analysis. Int J Mol Sci. 2021;22(5):2734. https://doi.org/10.3390/ijms22052734.</mixed-citation><mixed-citation xml:lang="en">Aboeldalyl S., James C., Seyam E. et al. The role of chronic inflammation in polycystic ovarian syndrome – a systematic review and meta-analysis. Int J Mol Sci. 2021;22(5):2734. https://doi.org/10.3390/ijms22052734.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Wu Q., Zhuang T., Li Z. Dexamethasone restores the repressive effect of tumor necrosis factor-α on follicular growth and E2 secretion during the in vitro culture of preantral follicles. Reprod Sci. 2021;28(11):3248–57. https://doi.org/10.1007/s43032-021-00521-6.</mixed-citation><mixed-citation xml:lang="en">Wu Q., Zhuang T., Li Z. Dexamethasone restores the repressive effect of tumor necrosis factor-α on follicular growth and E2 secretion during the in vitro culture of preantral follicles. Reprod Sci. 2021;28(11):3248–57. https://doi.org/10.1007/s43032-021-00521-6.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Brink H.V., Pea J., Lujan M.E. Ultrasonographic features of ovarian morphology capture nutritional and metabolic influences on the reproductive axis: implications for biomarker development in ovulatory disorders. Curr Opin Biotechnol. 2021;70:42–7. https://doi.org/10.1016/j.copbio.2020.</mixed-citation><mixed-citation xml:lang="en">Brink H.V., Pea J., Lujan M.E. Ultrasonographic features of ovarian morphology capture nutritional and metabolic influences on the reproductive axis: implications for biomarker development in ovulatory disorders. Curr Opin Biotechnol. 2021;70:42–7. https://doi.org/10.1016/j.copbio.2020.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu H., Ding G., Huang H. FSH regulates glucose-stimulated insulin secretion: a bell-shaped curve effect. J Diabetes. 2024;16(4):e13546. https://doi.org/10.1111/1753-0407.13546.</mixed-citation><mixed-citation xml:lang="en">Zhu H., Ding G., Huang H. FSH regulates glucose-stimulated insulin secretion: a bell-shaped curve effect. J Diabetes. 2024;16(4):e13546. https://doi.org/10.1111/1753-0407.13546.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Berry S., Seidler K., Neil J. Vitamin D deficiency and female infertility: a mechanism review examining the role of vitamin D in ovulatory dysfunction as a symptom of polycystic ovary syndrome. J Reprod Immunol. 2022;151:103633. https://doi.org/10.1016/j.jri.2022.103633.</mixed-citation><mixed-citation xml:lang="en">Berry S., Seidler K., Neil J. Vitamin D deficiency and female infertility: a mechanism review examining the role of vitamin D in ovulatory dysfunction as a symptom of polycystic ovary syndrome. J Reprod Immunol. 2022;151:103633. https://doi.org/10.1016/j.jri.2022.103633.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">de Medeiros S.F., Junior J.M.S., de Medeiros M.A.S. et al. Combined oral contraceptive use and obesity in women with polycystic ovary syndrome. A meta-analysis of randomized clinical trials. Arch Gynecol Obstet. 2024;310(4);2223–33. https://doi.org/10.1007/s00404-024-07637-5.</mixed-citation><mixed-citation xml:lang="en">de Medeiros S.F., Junior J.M.S., de Medeiros M.A.S. et al. Combined oral contraceptive use and obesity in women with polycystic ovary syndrome. A meta-analysis of randomized clinical trials. Arch Gynecol Obstet. 2024;310(4);2223–33. https://doi.org/10.1007/s00404-024-07637-5.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Luque-Ramírez M., Nattero-Chávez L., Ortiz Flores A.E., Escobar-Morreale H.F. Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2018;24(2):225–41. https://doi.org/10.1093/humupd/dmx039.</mixed-citation><mixed-citation xml:lang="en">Luque-Ramírez M., Nattero-Chávez L., Ortiz Flores A.E., EscobarMorreale H.F. Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2018;24(2):225–41. https://doi.org/10.1093/humupd/dmx039.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Practice Committee of the American Society for Reproductive Medicine. The use of hormonal contraception can be considered to aid in the timing of assisted reproductive technology cycles, reduce the risk of ovarian cysts at in vitro fertilization cycle initiation, and optimize visualization before hysteroscopy. Fertil Steril. 2024;122(2):243–50. https://doi.org/10.1016/j.fertnstert.2024.02.032.</mixed-citation><mixed-citation xml:lang="en">Practice Committee of the American Society for Reproductive Medicine. The use of hormonal contraception can be considered to aid in the timing of assisted reproductive technology cycles, reduce the risk of ovarian cysts at in vitro fertilization cycle initiation, and optimize visualization before hysteroscopy. Fertil Steril. 2024;122(2):243–50. https://doi.org/10.1016/j.fertnstert.2024.02.032.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Setiani R.E., Dwiningsih S.R., Sari G.M. Correlation between obesity and successful ovulation induction with Clomiphene citrate. Qanun Medika – Medical Journal Faculty of Medicine Muhammadiyah Surabaya. 2022;6(1). https://doi.org/10.30651/jqm.v6i1.8309.</mixed-citation><mixed-citation xml:lang="en">Setiani R.E., Dwiningsih S.R., Sari G.M. Correlation between obesity and successful ovulation induction with Clomiphene citrate. Qanun Medika – Medical Journal Faculty of Medicine Muhammadiyah Surabaya. 2022;6(1). https://doi.org/10.30651/jqm.v6i1.8309.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z., Van Faassen M., Groen H. et al. Resumption of ovulation in anovulatory women with PCOS and obesity is associated with reduction of 11β-hydroxyandrostenedione concentrations. Hum Reprod. 2024;39(5):1078–88. https://doi.org/10.1093/humrep/deae058.</mixed-citation><mixed-citation xml:lang="en">Wang Z., Van Faassen M., Groen H. et al. Resumption of ovulation in anovulatory women with PCOS and obesity is associated with reduction of 11β-hydroxyandrostenedione concentrations. Hum Reprod. 2024;39(5):1078–88. https://doi.org/10.1093/humrep/deae058.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">McGrice M., Porter J. The effect of low carbohydrate diets on fertility hormones and outcomes in overweight and obese women: a systematic review. Nutrients. 2017;9(3):204. https://doi.org/10.3390/nu9030204.</mixed-citation><mixed-citation xml:lang="en">McGrice M., Porter J. The effect of low carbohydrate diets on fertility hormones and outcomes in overweight and obese women: a systematic review. Nutrients. 2017;9(3):204. https://doi.org/10.3390/nu9030204.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Attia G.M., Almouteri M.M., Alnakhli F.T. Role of metformin in polycystic ovary syndrome (PCOS)-related infertility. Cureus. 2023;15(8):e44493. https://doi.org/10.7759/cureus.44493.</mixed-citation><mixed-citation xml:lang="en">Attia G.M., Almouteri M.M., Alnakhli F.T. Role of metformin in polycystic ovary syndrome (PCOS)-related infertility. Cureus. 2023;15(8):e44493. https://doi.org/10.7759/cureus.44493.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Эфендиева Р.М., Дикке Г.Б., Абусуева З.А., Шилова Н.В. Опыт восстановления менструального цикла у пациенток с олиго-/аменореей и ожирением с помощью комплекса, содержащего миоинозитол и D-хироинозитол в соотношении 5:1, фолиевую кислоту и марганец. Акушерство и гинекология. 2025;(2):110–20. https://doi.org/10.18565/aig.2025.31.</mixed-citation><mixed-citation xml:lang="en">Efendieva R.M., Dikke G.B., Abusueva Z.A., Shilova N.V. Experience of restoring menstrual cycle in patients with oligo-/amenorrhoea and obesity with a complex containing myoinositol and D-chiroinositol in the ratio 5:1, folic acid and manganese. [Opyt vosstanovleniya menstrual'nogo cikla u pacientok s oligo-/amenoreej i ozhireniem s pomoshch'yu kompleksa, soderzhashchego mioinozitol i D-hiroinozitol v sootnoshenii 5:1, folievuyu kislotu i marganec]. Akusherstvo i ginekologiya. 2025;(2):110–20. (In Russ.). https://doi.org/10.18565/aig.2025.31.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Foretz M., Guigas B., Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15(10):569–89. https://doi.org/10.1038/s41574-019-0242-2.</mixed-citation><mixed-citation xml:lang="en">Foretz M., Guigas B., Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15(10):569–89. https://doi.org/10.1038/s41574-019-0242-2.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Khodadadi M., Jafari-Gharabaghlou D., Zarghami N. An update on mode of action of metformin in modulation of meta-inflammation and inflammaging. Pharmacol Rep. 2022;74(2):310–22. https://doi.org/10.1007/s43440-021-00334-z.</mixed-citation><mixed-citation xml:lang="en">Khodadadi M., Jafari-Gharabaghlou D., Zarghami N. An update on mode of action of metformin in modulation of meta-inflammation and inflammaging. Pharmacol Rep. 2022;74(2):310–22. https://doi.org/10.1007/s43440-021-00334-z.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Barba M., Schünemann H.J., Sperati F. et al. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2009;70(5):661–70. https://doi.org/10.1111/j.1365-2265.2008.03459.x.</mixed-citation><mixed-citation xml:lang="en">Barba M., Schünemann H.J., Sperati F. et al. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2009;70(5):661–70. https://doi.org/10.1111/j.1365-2265.2008.03459.x.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Nie P., Wang M., Mo Y. et al. Metformin in gynecological disorders: pathogenic insights and therapeutic implications. Front Pharmacol. 2025;16:1526709. https://doi.org/10.3389/fphar.2025.1526709.</mixed-citation><mixed-citation xml:lang="en">Nie P., Wang M., Mo Y. et al. Metformin in gynecological disorders: pathogenic insights and therapeutic implications. Front Pharmacol. 2025;16:1526709. https://doi.org/10.3389/fphar.2025.1526709.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Bodepudi R., Seher S., Khan S.A. et al. Myoinositol versus metformin in the treatment of polycystic ovarian syndrome: a systematic review. Cureus. 2023;15(7):e41748. https://doi.org/10.7759/cureus.41748.</mixed-citation><mixed-citation xml:lang="en">Bodepudi R., Seher S., Khan S.A. et al. Myoinositol versus metformin in the treatment of polycystic ovarian syndrome: a systematic review. Cureus. 2023;15(7):e41748. https://doi.org/10.7759/cureus.41748.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Lin L., Chen G., Qiao X. et al. Comparative efficacy and safety of metformin, anti-obesity agents, and myoinositol in improving IVF/ICSI outcomes and reducing ovarian hyperstimulation syndrome in women with polycystic ovary syndrome: a systematic review and network metaanalysis. J Ovarian Res. 2024;17(1):249. https://doi.org/10.1186/s13048024-01576-0.</mixed-citation><mixed-citation xml:lang="en">Lin L., Chen G., Qiao X. et al. Comparative efficacy and safety of metformin, anti-obesity agents, and myoinositol in improving IVF/ICSI outcomes and reducing ovarian hyperstimulation syndrome in women with polycystic ovary syndrome: a systematic review and network metaanalysis. J Ovarian Res. 2024;17(1):249. https://doi.org/10.1186/s13048024-01576-0.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Zarezadeh M., Dehghani A., Faghfouri A.H. et al. Inositol supplementation and body mass index: a systematic review and meta-analysis of randomized clinical trials. Obes Sci Pract. 2021;8(3):387–97. https://doi.org/10.1002/osp4.569.</mixed-citation><mixed-citation xml:lang="en">Zarezadeh M., Dehghani A., Faghfouri A.H. et al. Inositol supplementation and body mass index: a systematic review and meta-analysis of randomized clinical trials. Obes Sci Pract. 2021;8(3):387–97. https://doi.org/10.1002/osp4.569.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
